Dupilumab in COPD

A new biologic agent, Dupilimab, may be a possible treatment for chronic obstructive pulmonary disorder. Join host, Geoff Wall, as he evaluates the use of dupilimab in COPD with Type 2 inflammation The GameChangerType 2 inflammation is driven by eosinophils and IL-4, 5, and 11. It occurs in 20% of patients with COPD. Dupilimab was able to decrease COPD exacerbations by 50% and improve symptoms HostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint Health ReferenceBhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. PMID: 37272521.https://www.nejm.org/doi/full/10.1056/NEJMoa2303951 Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Discuss the different phenotypes of COPD and treatment options2. Describe the BOREAS trial and the applicability to patients with COPD0.05 CEU/0.5 HrUAN: 0107-0000-23-288-H01-PInitial release date: 8/21/2023Expiration date: 8/21/2024Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram